Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC groups C09C, C09D and C09X (angiotensin II antagonists and renin inhibitors)

The Reimbursement Committee’s recommendation concerning the future reimbursement status of medicinal products in ATC groups C09C, C09D and C09X (angiotensin II antagonists and renin inhibitors) was open for consultation until 7 May 2010.

The Danish Medicines Agency received 12 consultation responses. The factbox to the right contains links to the consultation responses (in Danish only) and the Danish Medicines Agency’s announcement of 31 March 2010, where you can also find the Reimbursement Committee’s recommendation.

The Reimbursement Committee has discussed the consultation responses, which did not make the Committee change its recommendation. The Danish Medicines Agency now deliberates to reach a decision.

For further information, please contact the Reimbursement Department: Send an email.